BCLI · Brainstorm Cell Therapeutics Inc. · Executive Compensation
$0.84
-0.33 (-28.21%)
At close · Jul 18
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. Management’s plan includes raising funds from outside potential investors, however, as mentioned above, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives.”View the 10-Q filed Aug 14, 2026
Market Cap
$10.81M
Shares
11.03M
Volume · Jul 18
819.7K
Avg daily vol (3M)
1.39M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Stacy Lindborg | Co-Chief Executive Officer Uri Yablonka(\ ), Executive Vice President, Chief Business Officer, Secretary and Director | $1,007,725 |
| Ralph Kern | Former President & Former Chief Medical Officer | $833,192 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Stacy Lindborg | Co-Chief Executive Officer Uri Yablonka(\ ), Executive Vice President, Chief Business Officer, Secretary and Director | $851,543 |
| Ralph Kern | Former President & Former Chief Medical Officer | $812,559 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Ralph Kern | Former President & Former Chief Medical Officer | $938,833 |
| Stacy Lindborg | Co-Chief Executive Officer | $736,680 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Ralph Kern | President & Chief Medical Officer | $1,528,281 |
| Stacy Lindborg | EVP, Chief Development Officer | $867,505 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Peter J. Pitts | Chief Strategic Regulatory and Policy Officer | Appointed | 2026-07-30 |
| Jacob Frenkel | Senior Advisor | Appointed | 2026-07-30 |
| Peter J. Pitts | Executive Chairman | Appointed | 2026-07-30 |
| Ibrahim B. Dagher | Executive Vice President and Chief Medical Officer | Resigned | 2026-07-30 |
| Jacob Frenkel | Chairman of the Board | Resigned | 2026-07-30 |
| Jacob Frenkel | director | Resigned | 2026-07-30 |
| Peter J. Pitts | Board of Directors | Appointed | 2026-05-28 |
| Peter Pitts | director | Appointed | 2026-05-28 |
| Dr. Stacy Lindborg | Director | Appointed | 2024-09-16 |
| Nir Naor | Director | Appointed | 2024-09-16 |
| Dr. Menghisteab Bairu | Director | Appointed | 2024-09-16 |
| Uri Yablonka | Director | Appointed | 2024-09-16 |
| Dr. Anthony Polverino | Director | Appointed | 2024-09-16 |
| Dr. Jacob Frenkel | Director | Appointed | 2024-09-16 |
| Dr. Irit Arbel | Director | Appointed | 2024-09-16 |
| Hartoun Hartounian | Executive Vice President and Chief Operating Officer | Appointed | 2024-06-20 |
| Stacy Lindborg | member of the Board | Appointed | 2024-04-17 |
| Stacy Lindborg | Co-Chief Executive Officer | Resigned | 2024-04-17 |
| Nir Naor | member of the Board | Appointed | 2023-06-20 |
| Malcolm Taub | Board | Resigned | 2023-06-20 |
| David Setboun | Executive Vice President and Chief Operating Officer | Resigned | 2023-05-24 |